Genomic Medicine Sweden (GMS) has published the report Collaboration in Precision Medicine since 2017, which summarises recent developments in precision medicine in Sweden. The report shows how national collaboration between healthcare, academia, government agencies, patient organisations, and industry has, in just eight years, contributed to more patients gaining access to more accurate diagnostics and personalised treatment.
Since its inception in 2017, GMS has established seven regional Genomic Medicine Centres, implemented whole-genome sequencing in healthcare for rare diseases and childhood cancer, and developed national gene panels for blood cancers and solid tumours. Another important milestone is the creation of the National Genomics Platform (NGP), which enables secure storage and sharing of genomic data across the country.
“The report clearly shows the tremendous journey GMS has made since its start. It reflects the strength of national collaboration and how far we have come in making precision medicine accessible to patients throughout the country. We can now truly see the results of the combined efforts of healthcare regions, universities, and our partners—not least patient organizations and companies,” says Mats Ulfendahl, Chair of the GMS Steering Group and Director of Research at Region Östergötland.
The report also includes stories from patients who have received diagnoses and treatments thanks to genetic analysis, as well as examples of how GMS’s work has helped strengthen Swedish research, innovation, and international collaboration.
Read the report: Samverkan inom precisionsmedicin sedan 2017 (October 2025), in Swedish
Photo: Liza Samuelsson